DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Background: DNA methylation profiles have emerged as potential predictors of therapeutic response in various solid tumors.

Objective: This study aimed to analyze the DNA methylation profiles of patients with stage IV metastatic melanoma undergoing first-line immune checkpoint inhibitor treatment and evaluate their correlation with a radiological response according to immune-related Response Evaluation Criteria in Solid Tumors (iRECIST).

Methods: A total of 81 tissue samples from 71 patients with metastatic melanoma (27 female, 44 male) were included in this study.

Whole-Body [F]FDG-PET/MRI vs. [F]FDG-PET/CT in Malignant Melanoma.

Purpose: To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.

Procedures: We included patients with malignant melanoma who underwent a single injection [F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions.

Influence of Scanning Strategies on Processing of Aluminum Alloy EN AW 2618 Using Selective Laser Melting.

This paper deals with various selective laser melting (SLM) processing strategies for aluminum 2618 powder in order to get material densities and properties close to conventionally-produced, high-strength 2618 alloy. To evaluate the influence of laser scanning strategies on the resulting porosity and mechanical properties a row of experiments was done. Three types of samples were used: single-track welds, bulk samples and samples for tensile testing.

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

Several immunomodulatory checkpoint inhibitors have been approved for the treatment of patients with advanced melanoma, including ipilimumab, nivolumab and pembrolizumab. Talimogene laherparepvec is the first oncolytic virus to gain regulatory approval in the USA; it is also approved in Europe. Talimogene laherparepvec expresses granulocyte-macrophage colony-stimulating factor (GM-CSF), and with other GM-CSF-expressing oncolytic viruses in development, understanding the clinical relevance of this cytokine in treating advanced melanoma is important.